1. A Peptide Derived from IKK-Interacting Protein Attenuates NF-κB Activation and Inflammation.
- Author
-
Liu H, Yan Z, Zhao Y, Ma X, Zhang H, Wang X, Zhuang W, Zheng Y, Liu B, Zhang L, and Gao C
- Subjects
- Animals, Arthritis, Experimental chemically induced, Arthritis, Experimental drug therapy, Cell Line, Tumor, Enzyme Activation drug effects, Enzyme Activation genetics, Gene Expression Regulation drug effects, HEK293 Cells, Humans, Inflammation chemically induced, Inflammation drug therapy, Lipopolysaccharides adverse effects, Mice, Mice, Knockout, Protein Binding, Signal Transduction genetics, Zymosan adverse effects, I-kappa B Kinase metabolism, Intracellular Signaling Peptides and Proteins metabolism, NF-kappa B metabolism, Peptides administration & dosage, Signal Transduction drug effects
- Abstract
The IκB kinase (IKK) complex plays a vital role in regulating the NF-κB activation. Aberrant NF-κB activation is involved in various inflammatory diseases. Thus, targeting IKK activation is an ideal therapeutic strategy to cure and prevent inflammatory diseases related to NF-κB activation. In a previous study, we demonstrated that IKK-interacting protein (IKIP) inhibits the phosphorylation of IKKα/β and the activation of NF-κB through disruption of the formation of IKK complex. In this study, we identified a 15-aa peptide derived from mouse IKIP (46-60 aa of IKIP), which specifically suppressed IKK activation and NF-κB targeted gene expression via disrupting the association of IKKβ and NEMO. Importantly, administration of the peptide reduced LPS-induced acute inflammation and attenuated Zymosan-induced acute arthritis in mice. These findings suggest that this IKIP peptide may be a promising therapeutic reagent in the prevention and treatment of inflammatory diseases., (Copyright © 2021 by The American Association of Immunologists, Inc.)
- Published
- 2021
- Full Text
- View/download PDF